Washington State Bill Seeks to Legalize Medical Use of Psilocybin

January 18, 2022 15:50:00

Last week, two legislators from Washington State introduced a proposal that would legalize psilocybin services in the state. The bill, dubbed SB5660, would permit individuals aged 21 and above to consume products that contain psilocin and psilocybin under the supervision of a state-licensed and trained psilocybin service administrator. Psilocin and psilocybin are the two primary active ingredients found in magic mushrooms.

Individuals with certain medical conditions that render them unable to go to a licensed service center would be allowed to meet with facilitators remotely and be administered these products at home. Other individuals who don’t meet this criterion would be required to travel to a licensed service center.

In an interview, Mason Marks, who helped draft various sections of the proposal, stated that the measure built on the momentum of previous efforts of psilocybin policy reform across the country as well as in the state. For instance, Seattle became the biggest city in the country to decriminalize psychedelic substances after a city council measure was approved. Additionally, voters in the state of Oregon passed a measure to legalize supported psilocybin treatment for mental health conditions in November 2020.

This new state bill, which was sponsored by Sen. Liz Lovelett and Sen. Jesse Salomon, will also establish a legal psilocybin industry for legal age adults.

The bill states that internationally and nationally recognized medical institutions have demonstrated that psilocybin can be used to effectively treat various behavioral health conditions, including anxiety disorders, depression, end-of-life psychological distress and addiction.

During a recent interview, Salomon explained that research had shown that safe, guided and certified psilocybin services produced good results with regard to curing depression, anxiety and addiction, in comparison to other therapies. Salomon also noted that it was time to integrate the use of psilocybin in the community, given that mental health conditions have worsened during the pandemic.

SB 5660 also mandates the state’s Department of Health regulate the new industry and issue licenses. Additionally, a Washington Psilocybin Advisory Board will need to be established in the department to offer guidance on matters such as the best practices for supported use, social and scientific research, and a criterion for the measure’s social opportunity program.

In addition to this, the state’s health department will also be required to approve rules for a comprehensive regulatory framework during the development period once the measure is passed.

If the bill is approved, Washington’s health department will also be required to start receiving applications to operate a psilocybin service center, manufacture psilocybin products and facilitate psilocybin products testing or other such services from January 2024.

These developments bode well for the psychedelic industry’s march forward, and companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) will not have so much work to do popularizing their psychedelic-based formulations since the public is increasingly becoming aware of the potential of these substances.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.